Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients

Cardiovascular Therapeutics
Claudio BorghiSMILE-4 Working Party

Abstract

In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as diabetics. The adjusted rate of MACE was lower under zofenopril than under ramipril in both nondiabetics [27.9% vs. 34.9% ramipril; odds ratio, OR and 95% confidence interval: 0.55 (0.35, 0.86)] and diabetics [30.9% vs. 41.3%; 0.56 (0.18, 1.73)], although the difference was statistically significant only for the nondiabetic group (P = 0.013). Zofenopril was superior to ramipril as regards to the primary study endpoint in the subgroup of 157 patients with uncontrolled blood glucose (≥ 126 mg/dL), regardless of a previous diagnosis of diabetes [0.31 (0.10, 0.90), P = 0.030]. Zofen...Continue Reading

References

May 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·I MahéJ F Bergmann
Apr 17, 2002·Circulation·Martin E YoungHeinrich Taegtmeyer
May 22, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Bahi TakkouchePaula A Rochon
Aug 11, 2004·European Heart Journal·José López-SendónUNKNOWN Task Force on ACE-inhibitors of the European Society of Cardiology
Dec 25, 2004·Revista española de cardiología·José López-SendónUNKNOWN Comité de la ESC para la elaboracion de las Guías de Práctica Clínica
Jan 18, 2005·The Journal of International Medical Research·S Evangelista, S Manzini
Mar 16, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Ettore Ambrosioni
Apr 10, 2008·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Darren K McGuireEle Ferrannini
Sep 18, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Cecilia CialdaiCarlo Alberto Maggi
Oct 7, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Donatella MutoloTito Pantaleo
May 12, 2011·Cardiology Research and Practice·Bruce OvbiageleGregg C Fonarow
Sep 2, 2011·Trends in Pharmacological Sciences·James Matthew Luther, Nancy J Brown
Jan 4, 2012·Diabetes Care·UNKNOWN American Diabetes Association
May 9, 2012·Molecular and Cellular Endocrinology·Erik J Henriksen, Mujalin Prasannarong
Sep 26, 2012·Journal of the American Geriatrics Society·Ilene H ZuckermanBruce Stuart
Aug 3, 2013·Kardiologia polska·Filippo Del CorsoClaudio Borghi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.